CHC

Nahon P, Ziol M, Pan L, Portal JJ, Oberti F, Aube C, Blanc JF, Trillaud H, Merle P, Rode A, Assenat E, Guiu B, Lequoy M, Cornelis F, Bouattour M, Talib Z, Tibi A, Zeng Q, Bouda Y, Ganne-Carrié N, Sutter O, Sutton A, Guyot E, Barget N, Zucman-Rossi J, Campani C, Bamba-Funck J, Calderaro …

Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in patients with early hepatocellular carcinoma and high risk of recurrence (NIVOLEP trial). Lire la suite »

Odent AV, Campani C, Bouattour M, Touchefeu Y, Delhoume V, Rosmorduc O, Pascale A, An J, Lee HC, Regnault H, Thabut D, Amaddeo G, Ningararhi M, Olivier-Hourmand I, Metivier C, Ronot M, Ntandja-Wandji L, Ozenne V, Sidali S, Marra F, Hollande C, Ganne-Carrié N, Nahon P, Peron JM, Lequoy M, Sharma R, Paris Liver Cancer …

Clinical predictors of response to atezolizumab/bevacizumab in Child-Pugh B patients with hepatocellular carcinoma. Lire la suite »

Hobeika C, Cauchy F, Rode A, Salamé E, Scatton O, Schwarz L, Papadopoulos P, Hocquelet A, Manichon AF, Aubé C, Oberti F, Corte AD, Luciani A, Gay S, Lesurtel M, Lim C, Nahon P, Ganne-Carrié N, Blaise L, Soubrane O, Sutter O, Brustia R, Barbier L, Laurent A, Seror O, Nault JC. Liver Int. 2026 …

Laparoscopic or Open Liver Resection Versus Multibipolar Radiofrequency Ablation of HCC Within Milan Criteria on Cirrhosis. Lire la suite »

Campani C, Shim JH, Bouattour M, Touchefeu Y, Delhoume V, Rosmorduc O, Pascale A, An J, Lee HC, Regnault H, Thabut D, Amaddeo G, Ningarhari M, Ollivier-Hourmand I, Métivier C, Ronot M, Ntandaja-Wandji L, Ozenne V, Sidali S, Marra F, Hollande C, Ganne-Carrié N, Nahon P, Peron JM, Lequoy M, Sharma R, Paris Liver Cancer …

Long-term Survival and Cure Fraction in Patients with Advanced Hepatocellular Carcinoma under Immunotherapy in Randomized Controlled Trials and Real-world Data. Lire la suite »

Kanwal F, Feng Z, Hoshida Y, Chhatwal J, Wong VW, Ioannou GN, Nahon P, Lotter W, Ning J, Taouli B, Marquez G, Fu SW, Singal AG. Hepatology. 2026 Nov 1;84(5):1587-1604. Clinical practice guidelines recommend hepatocellular cancer (HCC) surveillance in patients with cirrhosis from any etiology and those with chronic hepatitis B virus (HBV) infection and …

Development and validation of risk stratification models for hepatocellular cancer: A framework from the translational liver cancer consortium. Lire la suite »

Nahon P, Oussalah A. J Hepatol. 2026 Oct 26:S0168-8278(26)02983-1. Pour lire l’article : voir sur PubMed

Merle P, Blanc JF, Le Malicot K, Peron JM, Bourgeois V, Bouattour M, Touchefeu Y, Vitellius C, Akouz FK, Heurgué A, Girot P, Assenat E, Nguyen-Khac E, Bronowicki JP, Viaud J, Ben Abdelghani M, Manfredi S, Edeline J, Phelip JM; TRIPLET-HCC study investigators. Lancet Gastroenterol Hepatol. 2026 Aug;11(8):700-712. Background: Patients with unresectable hepatocellular carcinoma have …

Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial. Lire la suite »

Nahon P, Layese R, Natella PA, Parlati L, Saidi T, Ganne-Carrié N, N’Kontchou G, Chaffaut C, Nault JC, Bamba-Funck J, Sutton A, Nzinga CL, Carrat F, Audureau E; ANRS CO12 CirVir, ANRS CO22 Hepather, and CIRRAL groups. JHEP Rep. 2026 Apr;8(4):101740. Background & aims: We aimed to develop machine learning (ML) models for hepatocellular carcinoma …

Comparative evaluation of regression and machine-learning models for hepatocellular carcinoma risk stratification across diverse aetiologies. Lire la suite »

Nault JC, Boubaya M, Wartski M, Dohan A, Pol S, Pop G, Soussan M, Sutter O, Costentin C, Roux J, Sengel C, Lequoy M, Montravers F, Menu Y, Pageaux GP, Goulart DM, Guiu B, Luciani A, Nahon P, Dioguardi Burgio M, Wagner M, Maksud P, Mulé S, Allaire M, Sidali S, Coilly A, Besson FL, …

[18F]fluorodeoxyglucose and [18F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre study Lire la suite »